Delving into the Latest Updates on NSC-620621 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Antineoplaston AS2-1, Astugenal

Target-

Mechanism-

Therapeutic Areas

NeoplasmsNervous System DiseasesOther Diseases

Active Indication-

Inactive Indication

Central Nervous System NeoplasmsDiffuse Intrinsic Pontine GliomaNeurilemmoma+ [1]

Originator Organization

Burzynski Research Institute, Inc.

Active Organization-

Inactive Organization

Burzynski Research Institute, Inc.

Drug Highest PhaseSuspendedPhase 2

First Approval Date-

Regulation-

Login to view timeline

The primary objective of this protocol study is to investigate the effect of Antineoplaston therapy on the QT/QTc interval in study subjects age 3 to 21 years with newly-diagnosed, diffuse, intrinsic brainstem glioma. This investigation is to be conducted in parallel with a phase 3 efficacy and safety study of combination Antineoplaston therapy + radiation vs. radiation alone (BRI-BT-52).

Start Date01 Jun 2027

Sponsor / Collaborator

Burzynski Research Institute, Inc.

NCT02887040 / Not yet recruitingPhase 3IIT

A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

Patients ≥ 3 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma will be enrolled in this study. However, the primary objectives of this study are to 1) compare overall survival, the time from randomization to death from any cause, for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma who receive Antineoplaston therapy (Atengenal + Astugenal) + radiation therapy vs. radiation therapy alone and 2) describe the toxicity profile (all subjects) for Antineoplaston therapy + radiation therapy vs. radiation therapy alone.
A secondary objective is to compare progression-free survival for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma treated with Antineoplaston therapy + radiation therapy vs. radiation therapy alone.

Start Date01 Jun 2025

Sponsor / Collaborator

Burzynski Research Institute, Inc.

NCT04542681 / WithdrawnPhase 1IIT

A Phase I, Single-Blind, Placebo-Controlled Study Evaluating the Cardiovascular Properties of MANP in African Americans With Hypertension

Evaluate the cardiovascular properties of MANP in AA with Hypertension

Start Date01 May 2018

Sponsor / Collaborator

Mayo Clinic

100 Clinical Results associated with NSC-620621

Login to view more data

100 Translational Medicine associated with NSC-620621

Login to view more data

100 Patents (Medical) associated with NSC-620621

Login to view more data

17

Literatures (Medical) associated with NSC-620621

01 Jan 2014·Oncology ReportsQ3 · MEDICINE

Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells

Q3 · MEDICINE

Article

Author: Yutaka Ogata ; Keiko Matono ; Yoshito Akagi ; Kazuo Shirouzu ; Masataka Ushijima ; Hideaki Tsuda

Antineoplastons are naturally occurring peptides and amino acid derivatives found in human blood and urine. antineoplastons have been shown to control neoplastic growth. In the present study, we investigated demethylation effect of the antineoplaston AS2-1 (a mixture of phenylacetylglutamine and phenylacetate in the ratio of 1:4) on various genes in colon cancer cells. An HpaII-MspI methylation microarray was used to investigate the methylation status of 51 genes at the promoter region in HCT116 and KM12SM human colon cancer cells before and after treatment of AS2-1. The expression of protein and mRNA of the demethylated genes by AS2-1 in HCT116 cells was evaluated. In 19 of the 34 methylated genes in HCT116 and in 7 of the 8 methylated genes in KM12SM, the methylation status was downregulated after treatment with 2 mg/ml of AS2-1 for 24 h. AS2-1 dramatically downregulated the methylation status of p15 and ESR1 in HCT116 cells and of MTHFR and MUC2 in KM12SM cells. Both mRNA and protein expression of p15 increased in a dose- and time-dependent manner after treatment with AS2-1. The antineoplaston AS2-1 may normalize the hypermethylation status at the promoter region in various genes including tumor suppressor genes, resulting in activation of the transcription and translation in colon cancer.

01 Apr 2009·Bioorganic & Medicinal ChemistryQ3 · MEDICINE

Novel aminopeptidase N inhibitors derived from antineoplaston AS2–5 (Part II)

Q3 · MEDICINE

Article

Author: Jifeng Wu ; Wenfang Xu ; Yonggang Li ; Xun Li ; Qiang Wang ; Yazhou Wang

As our ongoing work, a series of peptidomimetic L-iso-glutamine derivatives derived from antineoplaston AS2-5 scaffold were prepared and their APN/CD13 and MMP-2 inhibitory activities were evaluated hereby. The results displayed that these compounds exhibited selective inhibition against APN as compared with MMP-2, with IC(50) values in micromole range. Compounds A1 and A2 showed comparable APN inhibitory activities than the positive control bestatin.

01 Jun 2003·Surgery TodayQ4 · MEDICINE

Long-Term Survival Following Treatment with Antineoplastons for Colon Cancer with Unresectable Multiple Liver Metastases: Report of a Case

Q4 · MEDICINE

Article

Author: Keiko Matono ; Hideaki Tsuda ; Yoshito Akagi ; Yasumi Araki ; Tsutomu Kumabe ; Michio Sata ; Hiroshi Hara ; Kazuo Shirouzu ; Hideki Saitsu ; Yutaka Ogata

We report a case of survival for nearly 8 years after treatment of unresectable multiple liver metastases from colon cancer, using microwave ablation and the nontoxic antitumor agent, the antineoplastons. A 72-year-old man diagnosed with adenocarcinoma of the ascending colon and 14 bilateral liver metastases underwent a right hemicolectomy combined with microwave ablation of six metastatic liver tumors. We also decided to give antineoplastons to inhibit metastatic tumor growth and recurrence. Antineoplaston A10 was given intravenously, followed by oral antineoplaston AS2-1. Computed tomography scans done 1 and 4 years after the initial diagnosis showed recurrent tumors in S(4) and S(7), respectively. The patient underwent a second and a third microwave ablation of the recurrent tumors, and has survived for nearly 8 years without suffering any serious adverse effects. He is currently free from cancer. This case report demonstrates the potential effectiveness of the nontoxic antitumor agent, the antineoplastons, for controlling liver metastases from colon cancer.

100 Deals associated with NSC-620621

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diffuse Intrinsic Pontine Glioma	Phase 2	US	Burzynski Research Institute, Inc.	13 Apr 2016
Central Nervous System Neoplasms	Phase 2	US	Burzynski Research Institute, Inc.	01 Mar 1999
Neurilemmoma	Phase 2	US	Burzynski Research Institute, Inc.	01 Mar 1999
Neurofibroma	Phase 2	US	Burzynski Research Institute, Inc.	01 Mar 1999

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00003487 (CTgov)	Phase 2	Adenocarcinoma of Esophagus	8	Atengenal+Astugenal	vhsdqxyeur(vbtvgxgled) = psdsclljxp xgndmjywha (jkijkhgjin, iprcqvcjgm - qyedmltlyf) View more	-	14 May 2021
NCT00003508 (CTgov)	Phase 2	Mesothelioma, Malignant	8	Atengenal+Astugenal	gkkldmkvgn(bbtsfrszvi) = stdqohlqft gonqtyrnbv (bdwpatrioo, tgxffozywv - jyhjxzwlmo) View more	-	21 Feb 2021
NCT00003511 (CTgov)	Phase 2	Multiple Myeloma	5	Atengenal+Astugenal	mugimvnkgx(uaqddgwjqo) = glfpapjotr hnmsnwinne (krjygaztyy, chdxrzsdec - sdugvcxtid) View more	-	28 Jan 2021
NCT00003498 (CTgov)	Phase 2	Non-Hodgkin Lymphoma	5	Atengenal+Astugenal	oowldupylk(yolawosfar) = gblnnvzwig vaqqblpaxr (dozclbyhtk, letpdwsizm - tzcjzfindk) View more	-	19 Dec 2020
NCT00003509 (CTgov)	Phase 2	Melanoma	13	Atengenal+Astugenal	(cbyiemfjvh) = fxiddjxqzc zlililxgju (yxdnaqqaof, beralbukca - uaxxqhofsf) View more	-	19 Dec 2020
NCT00003526 (CTgov)	Phase 2	Adenocarcinoma \| Unknown Primary Neoplasms	8	Atengenal+Astugenal	(njkuhyvycl) = qfiooeyipi srpazjrhjf (fmquceujri, pnsbfmzply - dumjuuytuw) View more	-	17 Dec 2020
NCT00003531 (CTgov)	Phase 2	Pancreatic adenocarcinoma	15	Atengenal+Astugenal	zuyugakwsg(gzblhxptrd) = lhgczysvno xqqlfdyzbh (gtxhfkbmpy, vvicsnkzaa - grizjurdek) View more	-	17 Dec 2020
NCT00003492 (CTgov)	Phase 2	undifferentiated large cell lung cancer	9	Atengenal+Astugenal	cbckljbbuc(yeugjosslc) = bajulxlawf ysdbrnrbxh (vqukltyykw, emhmcciwmo - rrevhuzvcw) View more	-	16 Dec 2020
NCT00003499 (CTgov)	Phase 2	Low Grade B-Cell Non-Hodgkin's Lymphoma	31	Atengenal+Astugenal	(lnaktbcznd) = sonvzhyxpy ghwxajmyap (nkqetrqljm, bltjeeqahz - wsduuljtdf) View more	-	16 Apr 2019
NCT00003453 (CTgov)	Phase 2	Adrenocortical Carcinoma	6	Atengenal+Astugenal	(ebqhxuyolm) = btegdkmecs obkdttosjg (rbcmgdvdft, eomjasutlf - ytaphejeib) View more	-	09 May 2018